Vol. 125, No. 4 October–December 1957

JAN 13 1958

The Journal of NERVOUS AND MENTAL DISEASE

An Educational Journal of Neuropsychiatry, founded in 1874

MANAGING EDITOR
NOLAN D. C. LEWIS, M.D., *Princeton*

ASSOCIATE MANAGING EDITOR
A. N. FOXE, M.D., *New York*

ASSOCIATE EDITORS
PERCIVAL BAILEY, M.D., *Chicago*
KURT GOLDSTEIN, M.D., *New York*

Published quarterly by
THE WILLIAMS & WILKINS COMPANY
BALTIMORE 2, MARYLAND

COPYRIGHT 1958, THE WILLIAMS & WILKINS COMPANY

Managing Editor
NOLAN D. C. LEWIS, M.D.
New Jersey Neuro-Psychiatric Institute
Box 1000
Princeton, New Jersey

Associate Managing Editor
A. N. FOXE, M.D., *New York*
Associate Editors
PERCIVAL BAILEY, M.D., *Chicago*
KURT GOLDSTEIN, M.D., *New York*

With the Collaboration of

A. AUSTREGESILO, M.D., *Rio de Janeiro, Brazil*
FRANCIS J. BRACELAND, M.D., *Hartford, Conn.*
LOUIS CASAMAJOR, M.D., *New York, N. Y.*
RUSSELL N. DEJONG, M.D., *Ann Arbor, Mich.*
JEAN DELAY, M.D., *Paris, France*
FREDERIC J. FARNELL, M.D., *New York, N. Y.*
JOHN F. FULTON, M.D., *New Haven, Conn.*
BERNARD GLUECK, M.D., *New York, N. Y.*
C. JUDSON HERRICK, Ph.D., *Chicago, Ill.*
MARION HINES, M.D., *Emory University, Ga.*
GORDON HOLMES, M.D., *London, England*
BEN KARPMAN, M.D., *Washington, D. C.*
ABRAHAM MOSOVICH, M.D., *Buenos Aires, Argentina*
WINFRED OVERHOLSER, M.D., *Washington, D. C.*
JEAN SAUCIER, M.D., *Montreal, Canada*
ALBERTO SEGUIN, M.D., *Lima, Peru*
E. A. SHARP, M.D., *Buffalo, N. Y.*
EDWARD A. STRECKER, M.D., *Philadelphia, Pa.*
L. VAN DER HORST, M.D., *Amsterdam, Holland*
HENRY R. VIETS, M.D., *Boston, Mass.*

Child Psychiatry Service
THE MENNINGER FOUNDATION

THE SOUTHARD SCHOOL

A residential school for elementary grade children with emotional and behavior problems.

THE CHILDREN'S CLINIC

Outpatient psychiatric and neurologic evaluation of infants and children to eighteen years.

ROBERT SWITZER, M.D., *Director*

Topeka, Kansas; Telephone CEntral 3-6494

TWENTY MINUTES FROM TIMES SQUARE, BROOKLYN AND BRONX

River Crest Sanitarium

DITMARS BLVD. & 26TH STREET — ASTORIA, L.I., NEW YORK CITY

Modern Facilities for the individual care and treatment of Nervous, Mental and Alcoholic Patients.

LAYMAN R. HARRISON, M.D.
Physician in Charge

MARTIN DOLLIN, M.D.
Clinical Director

Telephone Astoria 8-8442

Published monthly by The Williams & Wilkins Co., Mt. Royal and Guilford Aves., Baltimore 2, Md., U.S.A.
Subscription price $14.00, single issue $1.50
Second class mail privileges authorized at Baltimore, Md.

The Journal of Nervous and Mental Disease

Vol. 125, No. 4 October–December Serial No. 904

CONTENTS

The Influence of Seizure Perception on Seizure Occurrence. B. S. Aaronson 507
Removal of Cerebral Angioma with Cardiac Monitor. S. Rosner 511
Effect of Auditory Stress on Rats Implanted with Human Tumors. M. Bard, P. C. Merker and S. E. Waxenberg 513
Body Image and Paralytic Poliomyelitis. B. Z. Lebovitz and M. Lakin 518
Perceptual Rhythmic Dysfunction in Unilateral Disequilibrium. L. Halpern, E. Bental and S. Kugelmass 524
Promazine Treatment of Chronic Psychoses in 100 Hospitalized Patients. M. K. Frain 529
The Process of Demyelination in the Central Nervous System. IV. Demyelination as a Delayed Residual of Carbon Monoxide Asphyxia. C. B. Courville 534
Psychophysiologic Resistance in Insulin Coma Therapy. E. S. Patterson 547
Spatial Differentiation in Chronic Schizophrenia. M. H. Miller and J. W. Chotlos 558
Some Possible Meanings of the Hallway Interview. N. S. Brandes 564
A Rapid Interdisciplinary Method for Neuropsychiatric Evaluation of Family Groups. W. Offenkrantz and J. R. Whittier 570
Simultaneous Occurrence of Paget's Disease of the Skull and Brain Tumor. P. Gal 574
A Concept of Schizophrenia. S. R. Ovshinsky 578
Reverberating Circuits. D. Stanley-Jones 587
Posture and the Rhinencephalon. D. Stanley-Jones 591
Normality, Neurosis and Psychosis. M. H. Hollender and T. S. Szasz 599
The Effect of Death on the Psychiatric Situation of the Relatives. M. Sugar and C. Watkins 608
An Evaluation of Commonly Used Criteria for the Detection of Seizures in Succinylcholine and Atropine Modified ECT. S. Furman, B. S. Mersereau, W. A. Mann and R. H. Phillips 611
Neurologic Aspects of the Body-Mind Problem. E. A. Spiegel 614
Emotion as Frustrational Behavior. N. Bull 622
Losses and Depression. L. L. Havens 627
The Differential Incidence of Rheumatic Fever in the Histories of Paranoid and Non-Paranoid Schizophrenics. N. Wertheimer 637
Book Reviews 642
Notes and News 647
Index 651


The devil

still talks to me

but I don't bother to holler back. . . ."[1]

Manic, hallucinating . . . In acute psychotic agitation, the direct purpose of SPARINE is to quiet the hyperactivity. When hallucinations are present, they are either abolished or made less important and less frightening to the patient.

SPARINE is a well-tolerated and dependable agent when used according to directions. It may be administered intravenously, intramuscularly, or orally. Parenteral use offers (1) minimal injection pain; (2) no tissue necrosis at the injection site; (3) potency of 50 mg. per cc.; (4) no need for reconstitution before injection.
Comprehensive literature is available on request.

1. Fazekas, J.F., et al.: J.A.M.A. *161*:46 (May 5) 1956.

Wyeth®
Philadelphia 1, Pa.

Sparine®

HYDROCHLORIDE

Promazine Hydrochloride — *10-(γ-dimethylamino-n-propyl)-phenothiazine hydrochloride*

Typical case: "unmanageable" schizophrenic patient is hostile, untidy and inaccessible to therapy.

the "before-and-after" picture in mental wards continues to improve, case after case, with **Serpasil**® (reserpine CIBA)

With Serpasil, patient becomes calm, cooperative, amenable to interview . . . as have thousands in this new age of hope for the psychotic.

SUPPLIED:

Parenteral Solution:
Ampuls, 2 ml., 2.5 mg. Serpasil per ml.
Multiple-dose Vials, 10 ml., 2.5 mg. Serpasil per ml.

Tablets, 4 mg. (scored), 2 mg. (scored), 1 mg. (scored), 0.25 mg. (scored) and 0.1 mg.

Elixirs, 1 mg. and 0.2 mg. Serpasil per 4-ml. teaspoon.

CIBA
SUMMIT, N. J.

mg.

s, 10 ml.,
per ml.

ed), 2 mg.
ored),
and 0.1 mg.

2 mg.
teaspoon.

for those with

PARKINSONISM

"... in our experience procyclidine (Kemadrin) proved a worthy addition to the therapy of parkinsonism, because it afforded relief to many patients who had failed to respond to other drugs. It exerts an action against all symptoms of parkinsonism ... hence it may be employed as the basic drug in commencing treatment with new cases."

Zier, A. and Doshay, L. J.: Procyclidine Hydrochloride (Kemadrin) Treatment of Parkinsonism in 108 Patients, Neurology (July) 1957.

"... in our series of 30 severe Parkinsonism sufferers, 21 obtained moderate to good relief with the use of this new agent, Kemadrin, in combination with other drugs."

Lerner, P. F.: Kemadrin, a New Drug for Treatment of Parkinsonian Disease, J. Nerv. & Ment. Dis. 123:79 (Jan.) 1956.

Smoother activity,
and *brighter expression*

with **'KEMADRIN'**®

Also indicated for the treatment of drug-induced symptoms resembling parkinsonism, developing during treatment of mental patients.

'KEMADRIN' brand Procyclidine Hydrochloride
Tablets of 5 mg., scored. Bottles of 100 and 1,000.

BURROUGHS WELLCOME & CO. (U.S.A.) INC., Tuckahoe, N.Y.

ANNOUNCING:

Phosphatabs* (alkaline) with Teswells*

for routine precaution during tranquilizer therapy

In the past, routine screening for the detection of impending jaundice due to tranquilizers has not been possible. With new PHOSPHATABS, impending jaundice can be detected simply, rapidly, frequently—and at nominal cost.

The PHOSPHATABS technic offers a color-chart index of hepatic sensitization as revealed through the serum alkaline phosphatase level—the proven index. PHOSPHATABS testing is rapid—read in less than 30 minutes. PHOSPHATABS procedure is simple—quickly learned, easily performed. PHOSPHATABS results are unequivocal: *Normal . . . Borderline . . . Low Pathological . . . High Pathological.*

PHOSPHATABS—unlike older alkaline phosphatase technics—require no instruments.

NEW! a simple technic to detect incipient, latent and subclinical jaundice

Here is the recommended procedure when tranquilizers are instituted:

Determine serum alkaline phosphatase level with PHOSPHATABS at start of therapy and twice a week for the first 3 weeks. If level rises above normal, discontinue therapy. Continue twice-weekly alkaline phosphatase testing. When level is again normal, the tranquilizer may be reinstituted. For the next 10 days, check phosphatase levels twice weekly. If no rise occurs, hepatic desensitization has taken place.[1,2]

procedure:

1. Place 1 PHOSPHATABS tablet in the Teswell.
2. Add 4 drops of the patient's serum or plasma.
3. Break up the tablet with an applicator stick.
4. Let stand for 12-30 minutes, depending on room temperature (determine time from table in PHOSPHATABS package insert).
5. Add 1 drop of color developer.
6. Compare color with color chart provided.

Phosphatabs are available as a kit containing enough reagent tablets, Teswells (controlled-diameter test tubes) and color developer for 48 determinations, $15.00.

1. Shay, H., and Siplet, H.: Gastroenterology *32*: 571 (April) 1957.
2. Dickes, R.; Schenker, V., and Deutsch, L.: New England J. Med. *256*:1 (Jan. 3) 1957.

Order from your nearest laboratory supply distributor or write for more information to

Laboratory Supply Division
WARNER-CHILCOTT
MORRIS PLAINS, N. J.



the most advanced unidirectional current instrument for all established techniques

REITER MODEL RC-47D GREATLY MINIMIZES CONFUSION

The means to significantly minimize confusion is provided for in the versatile Model RC-47D. Patients are quiet and usually capable of returning to work following treatment. Fear of further treatment is greatly relieved in most patients. Efficiency of current increased. One knob control. Automatic safeguards assure an amazing reduction of thrust and apnea. The patient is often breathing before the completion of the seizure. Extremely rugged, the RC-47D withstands very long periods of use all the while maintaining the accuracy vital to delicate work within the brain. Patients resistant to all other electroshock, insulin and lobotomy forms of therapy have been successfully treated by modalities contained in Model RC-47D.

MODEL RC-47D PROVIDES FOR:

- CONVULSIVE THERAPY—*full range*
- NON-CONVULSIVE THERAPIES
- ELECTRO-SLEEP THERAPY
- FOCAL TREATMENT—*unilateral and bilateral*
- MONO-POLAR TREATMENT—*non-convulsive or convulsive*
- BARBITURATE COMA *and other respiratory problems*

ONLY REITER, THE ORIGINAL UNIDIRECTIONAL CURRENT ELECTROSTIMULATORS, ARE AUTHENTICALLY BACKED BY EXTENSIVE CLINICAL EXPERIENCE WITH OVER 200 REFERENCES IN LITERATURE AND TEXT-BOOKS.

REUBEN REITER, Sc.D.

64 WEST 48th STREET, NEW YORK 36, N. Y.

SEDATION
AND EUPHORIA FOR NERVOUS
IRRITABLE PATIENTS

Use
VALERIANETS-DISPERT
Reg. U. S. Pat. Off.

Each Chocolate Coated Tablet Contains Est. Valerian (highly concentrated) 0.05 Gm. dispergentized finely subdivided for maximum efficiency
TASTELESS, ODORLESS, NON-DEPRESSANT SEDATIVE and EUPHORIC
VALERIANETS-DISPERT are indicated in cases of nervous escitement and exhaustion, anxiety and depressive states, cardiac and gastrointestinal neuroses, menopausal and menstrual molimena, insomnia.
Dose: 1 or 2 tablets t.i.d. — Bottle of 50 and of 100 tablets
At All Prescription Pharmacies

STANDARD PHARMACEUTICAL CO. INC.
253 West 28th St.
New York 1, N. Y.

For Intestinal Dysfunction
NUCARPON®
Each tablet cont: Extract of Rhubarb, Senna, Precip. Sulfur, Peppermint Oil, Fennel Oil in activated charcoal base.

For making Burow's Solution U.S.P. XIV
WET DRESSING Use
PRESTO-BORO®
(Aluminum Sulfate and Calcium Acetate)
POWDER IN ENVELOPES
— TABLETS —
For treatment of Swellings, Inflammations, Sprains

For Pulmonary Conditions
TRANSPULMIN®
3% solution Quinine with 2½% Camphor for Intramuscular Injection.

ROGERS MEMORIAL HOSPITAL

(A non-stock, non-profit corporation.)



OCONOMOWOC, WISCONSIN

Phone Logan 7-5535

Thirty miles west of Milwaukee, providing the ideal, restful country environment and the facilities for the modern methods of therapy of the psychoneuroses, psychosomatic disorders, and the other neurologic and psychiatric problems. Occupational therapy and recreational activities.

Owen Otto, M.D., Med. Director
Eugene Frank, M.D.,
William H. Dushack, M.D.
Loren J. Driscoll, M.D.
LeRoy A. Wauck, Ph.D., Clinical Psychologist

MILWAUKEE SANITARIUM FOUNDATION, INC.

Wauwatosa, Wisconsin

Maintaining the highest standards since 1884, the Milwaukee Sanitarium Foundation continues to stand for all that is best in the physiological and psychotherapeutic treatment of neuropsychiatric disorders. Literature sent on request.

Carroll W. Osgood, M.D.,
Medical Director
Benjamin A. Ruskin, M.D.,
Asso. Medical Director
William T. Kradwell, M.D
Lewis Danziger, M.D.
James A. Alston, M.D.
Edward Carl Schmidt, M.D.
William L. Lorton, M.D.
Donald G. Ives, M.D.
Isaac J. Sarfatty, M.D.
Edward A. Birge, M.D.

Waldo W. Buss, *Executive Director*



COLONIAL HALL
One of the 14 Units in "Cottage Plan"

for the depressed and regressed

selective increase in psychic energy

MARSILID

(iproniazid) Roche

In both mild and severe depression, Marsilid can restore a sense of healthy well-being, with renewed vigor, activity and interests. Patients with acute depression refractory to shock treatment have shown a heartening response to Marsilid. Even "burned out" psychotics, untouched by any other therapy, have become more alert, responsive and sociable.

As a psychic energizer, Marsilid is truly unique. It provides continuous mood improvement with gradually reduced dosage. Patients do not develop resistance to its normalizing effect; there is no tachyphylaxis. Marsilid does not elevate blood pressure . . . does not decrease but usually stimulates appetite.

In mild depression, improvement with Marsilid is usually evident within a week or two. In severe depressive states of hospitalized psychotics, a month or more may be required for apparent response . . . but Marsilid often leads to complete remission, obviating the need for shock therapy.

Note: Marsilid is contraindicated in patients who are agitated, overactive or overstimulated, or in those with a history of renal or hepatic disease.

For complete references and information concerning dosage, indications and contraindications, write V. D. Mattia, Jr., M. D., Director of Medical Information, Roche Laboratories, Division of Hoffmann-La Roche Inc, Nutley 10, N. J.

MARSILID® PHOSPHATE – brand of iproniazid phosphate
Supplied in scored tablets of 50 mg (yellow), 25 mg (orange), and 10 mg (pink)

ROCHE *Original Research in Medicine and Chemistry*

Typical case: "unmanageable" schizophrenic patient is hostile, untidy and inaccessible to therapy.

the "before-and-after" picture in mental wards continues to improve, case after case, with **Serpasil**® (reserpine CIBA)

With Serpasil, patient becomes calm, cooperative, amenable to interview . . . as have thousands in this new age of hope for the psychotic.

SUPPLIED:

Parenteral Solution:
Ampuls, 2 ml., 2.5 mg. Serpasil per ml.
Multiple-dose Vials, 10 ml., 2.5 mg. Serpasil per ml.

Tablets, 4 mg. (scored), 2 mg. (scored), 1 mg. (scored), 0.25 mg. (scored) and 0.1 mg.

Elixirs, 1 mg. and 0.2 mg. Serpasil per 4-ml. teaspoon.

CIBA
SUMMIT, N. J.

THE JOURNAL OF
Nervous and Mental Disease

An Educational Journal of Neuropsychiatry
FOUNDED IN 1874

Published quarterly, one volume a year. Subscription price $7.00 per year, $7.25 in Canada, and $7.75 foreign and postal union. Subscriptions should be sent to the publisher.

New subscriptions and renewals are entered to begin with the first issue of the year when subscription is received. Should any issue of that volume be out of print when subscription is received, the pro-rata value will be refunded to the subscriber.

Subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Claims for copies lost in the mails must be received within 30 days (domestic).

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of a single issue ($2.25).

Correspondence concerning business matters should be addressed to the publisher.

INSTRUCTIONS TO AUTHORS

Manuscripts and correspondence pertaining thereto should be addressed to the Editor: Dr. Nolan D. C. Lewis, New Jersey Neuro-Psychiatric Institute, Box 1000, Princeton, N. J.

Manuscripts should be typewritten double spaced. Only the original will be accepted for publication. Handwritten corrections must be legible and kept to a minimum.

Footnotes should be omitted unless very brief. Material usually placed in footnotes should be incorporated in the text.

Bibliographies should be in alphabetical order, un-numbered, and should include name of author, title of article, name of journal, volume, page and year. When books are cited, include author, title, year of publication and publisher.

Illustrations for halftones should be glossy photographic prints; for line engravings, drawings should be made with India ink on white paper or blue graph paper.

The editorial office should be notified promptly of any change of address.

Galley proofs are sent to the author. Authors will be billed for the total cost of all cuts, tabular matter and alterations.

A table showing cost of reprints, with an order slip, is sent with proof.

Authors will receive one invoice which covers cost of reprints, cuts, tabular matter and alterations.

THE WILLIAMS & WILKINS COMPANY

Publishers of Scientific Books and Periodicals

Mt. Royal and Guilford Aves. Baltimore 2, Md., U.S.A.

Typical case: "unmanageable" schizophrenic patient is hostile, untidy and inaccessible to therapy.

the "before-and-after" picture in mental wards continues to improve, case after case, with **Serpasil**® (reserpine CIBA)

With Serpasil, patient becomes calm, cooperative, amenable to interview . . . as have thousands in this new age of hope for the psychotic.

SUPPLIED:

Parenteral Solution:
Ampuls, 2 ml., 2.5 mg. Serpasil per ml.
Multiple-dose Vials, 10 ml., 2.5 mg. Serpasil per ml.

Tablets, 4 mg. (scored), 2 mg. (scored), 1 mg. (scored), 0.25 mg. (scored) and 0.1 mg.

Elixirs, 1 mg. and 0.2 mg. Serpasil per 4-ml. teaspoon.

CIBA
SUMMIT, N. J.